UC69: Clinical Pharmacist Review (MTM)

The Problem

Polypharmacy (patients on 5+ medications) is increasingly common in elderly and multi-comorbid populations. Polypharmacy increases risk of drug-drug interactions, duplicate therapy, and inappropriate medications. Medicare Part D requires Medication Therapy Management (MTM) programs for eligible beneficiaries (typically those taking 5+ Part D drugs with annual out-of-pocket spending >$4,700). Pharmacists must manually identify MTM-eligible patients, review medication lists for interactions and appropriateness, and generate clinical recommendations. Manual review is time-intensive and reactive. Many eligible patients never receive MTM due to resource constraints.

What the Agent Does

MTM Eligibility Screening: Identifies all Medicare Part D beneficiaries meeting MTM criteria (5+ Part D drugs, $4,700+ annual spend); prioritizes patients by medication complexity and interaction risk.
Interaction & Duplication Analysis: Performs comprehensive drug-drug and drug-disease interaction checking using Lexicomp/Micromedex databases; identifies duplicate therapy (e.g., two NSAIDs prescribed concurrently); generates severity-ranked interaction list.
Deprescribing Recommendations: Identifies medications appropriate for discontinuation per deprescribing guidelines (e.g., statins in very elderly with limited life expectancy, benzodiazepines in fall-risk patients); provides clinical rationale and tapering protocols.
Dose Appropriateness Checking: Evaluates doses against renal/hepatic function, patient age, and clinical guidelines; flags doses that are excessive or suboptimal.
MTM Clinical Summary Generation: Compiles agent findings into MTM clinical summary report ready for pharmacist review; includes interaction severity, deprescribing recommendations, and dose adjustments; prioritizes recommendations by clinical impact.
Pharmacist Handoff & Documentation: Generates suggested MTM documentation template for pharmacist; tracks which recommendations were accepted/rejected; updates medication records if pharmacist approves changes.

Data Requirements

Aspect	Details
Data Sources	Medicare Part D claims data (CMS), active medication list (pharmacy system), diagnosis codes (EHR), lab results (renal function, liver function), prior authorization history, deprescribing guidelines (American Geriatrics Society, CDC). Systems: pharmacy dispensing, EHR, PBM claims system.
Data Classification	PHI (medication list, lab results, claims data), CMS Part D data classification
Data Quality Needs	High , medication list must be current; diagnosis codes must reflect active conditions; lab values must be recent (within 6 months).
Complexity	Moderate-to-High , interaction database queries, renal dosing calculations, guideline interpretation.

Score Breakdown

Criterion	Weight	Score (1-5)	Weighted
Time Recaptured	15%	4	0.60
Error Reduction	10%	3	0.30
Cost Avoidance	10%	4	0.40
Strategic Leverage	5%	3	0.15
Data Availability	15%	3	0.45
Process Clarity	15%	3	0.45
Ease of Implementation	10%	3	0.30
Fallback Available	10%	4	0.40
Audience (Int/Ext)	10%	4	0.40
Composite	100%		3.65

Why It Scores Well

CMS Mandate & Quality Metric: MTM is a CMS requirement for certain beneficiaries; agent ensures compliance and increases reach.
Clinical Evidence Strong: MTM interventions reduce hospitalizations and adverse events; ROI demonstrated in literature.
Scale & Frequency: Applies to millions of Medicare beneficiaries; can be executed monthly for continuous optimization.
Pharmacist Productivity Enabler: Frees pharmacist time from manual chart review to focus on clinical judgment and patient counseling.
Low Regulatory Burden: MTM is established program; agent automates existing workflows with no new regulatory requirements.

Regulatory Alignment

CMS Part D MTM Requirements: Agent screens for eligibility per CMS criteria; generates required documentation; supports compliance audits.
HIPAA: All patient data handled securely; access audited; only authorized users access MTM summaries.
State Pharmacy Practice Acts: Pharmacist retains clinical responsibility; agent provides recommendations only; pharmacist makes final medication decisions.
Joint Commission: MTM programs contribute to patient safety standards.

Sprint Factory Fit

High Fit. Data integration straightforward (pharmacy + PBM systems). Interaction checking via mature APIs (Lexicomp, Micromedex). Deprescribing guidelines can be coded as decision trees. Initial build: 4 weeks for core MTM eligibility + interaction checking. Integration with EHR/pharmacy: 2 weeks. Deployment: Batch job running monthly + interactive pharmacist dashboard.

Comparable Implementations

Mirixa MTM Platform , MTM program baseline.
OutcomesMTM Pharmacist Tools , Clinical pharmacist support platform.
CMS Part D MTM Requirements Documentation , Regulatory framework reference.

Deploy This Use Case with the Sprint Factory

From zero to a governed, production agent in 6 weeks.

Sprint Factory Schedule a Briefing

Related Use Cases

Workflow Pharmacy/Clinical

Pharmacy Prior Authorisation (Provider Side)

Score: 3.9/5.0

Real-Time Pharmacy/Clinical

Opioid Risk Scoring Agent

Score: 3.85/5.0

On-Demand Pharmacy/Clinical

Pill Identification Agent

Score: 3.35/5.0

Governance Risks to Consider

Before deploying this use case, review these agentic AI risks from the Corvair Risk Catalogue. Each is scored on the DAMAGE framework and mapped to regulatory expectations.